Related Experiment Video
Updated: Jul 7, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Optimizing diabetes treatment using an amylin analogue.
1University of California San Diego, Veterans Affairs Medical Center, 3350 La Jolla Village Drive (111G), San Diego, CA 92161, USA.
The Diabetes Educator
|March 7, 2008
Summary
Pramlintide, a synthetic amylin analog, helps manage diabetes by regulating glucose and reducing insulin needs. This treatment improves post-meal glucose control and overall health for both type 1 and type 2 diabetes patients.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Traditional diabetes treatment focuses on insulin replacement or enhancement.
- Emerging understanding recognizes diabetes as a multi-hormonal disorder affecting glucose homeostasis.
- Patients with diabetes exhibit deficiencies in both insulin and amylin, contributing to postprandial hyperglycemia.
Purpose of the Study:
- To evaluate the efficacy of pramlintide, a synthetic amylin analog, in managing diabetes.
- To explore pramlintide's role in restoring glucose homeostasis by targeting glucoregulatory hormones beyond insulin.
- To assess pramlintide's impact on postprandial glucose control, insulin requirements, and body weight.
Main Methods:
- Utilized long-term studies to assess the effects of pramlintide.
- Investigated pramlintide's mechanisms of action, including effects on gastric emptying, glucagon secretion, and satiety.
- Monitored improvements in postprandial glucose fluctuations and glycosylated hemoglobin levels.
Main Results:
- Pramlintide demonstrated significant improvements in postprandial glucose fluctuations.
- Long-term use of pramlintide led to reduced glycosylated hemoglobin levels.
- Patients treated with pramlintide required less insulin and experienced reduced body weight.
Conclusions:
- Pramlintide effectively addresses amylin deficiency in diabetes, complementing insulin therapy.
- The multifaceted actions of pramlintide contribute to improved glycemic control and reduced metabolic burden.
- Pramlintide presents a valuable therapeutic option for individuals with type 1 and type 2 diabetes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...